Aethlon Medical Stock Plunges 10.37% Amid Sector Weakness

Aethlon Medical's stock experienced a significant drop of 10.37% in pre-market trading on September 4, 2025, amidst a broader sector weakness and concerns over share dilution.

The decline in Aethlon Medical's stock is part of a broader downturn in the medical device sector, which has been underperforming due to concerns about healthcare spending constraints and regulatory headwinds. The sector leader, Medtronic, also retreated, adding to the bearish sentiment.

Investors are scrutinizing whether this is a sector-wide selloff or a company-specific crisis. The broader medical device sector is underperforming, with Medtronic down and STRATA Skin Sciences' peers like Aethlon Medical also declining. However, STRATA’s 22% drop is far steeper than the sector’s average, indicating company-specific distress.

STRATA Skin Sciences' stock collapse is directly tied to its announced $2.42 million registered direct offering at $2.204/share, a 22% discount to its previous close of $2.83. This aggressive dilution—selling 1.1 million new shares—signals acute liquidity pressure and erodes shareholder value. The offering price of $2.204 is also below the stock’s 200-day moving average of $2.58, amplifying bearish sentiment.